Select your country
Select a country to go to the website of the respective STADA sales company.
Czech Republic (2)
Saudi Arabia (1)
The Phillippines (1)
United Arab Emirates (1)
United Kingdom (3)
STADA set for continuity: Peter Goldschmidt to succeed Claudio Albrecht as CEO on 1 September 2018
- Investor News
- Press Release
- Experienced generics expert Peter Goldschmidt committed to pursuing further growth
- Albrecht to continue course of renewal at STADA and then take on non-executive role as previously announced
Bad Vilbel, February 1, 2018 – Peter Goldschmidt (53) will join STADA Arzneimittel AG on 1 September 2018 and will succeed Claudio Albrecht as CEO. A resolution to that effect was passed at a meeting of the company's supervisory board today. An experienced manager in the OTC and generic drug segment, Goldschmidt will build on the successful course of renewal and growth at STADA which Claudio Albrecht will continue pursuing until the transition of the CEO role. As previously announced, Albrecht will then move on to a non-executive position within the group of companies.
Goldschmidt is joining the company from Novartis where he has held various leadership positions in Europe, Asia and the U.S. over the past 28 years. He is currently President of Sandoz USA and Head North America. Under his leadership, the company has significantly grown its generics and biosimilars business over the past five years. With more than USD 3bn in revenues, it expanded its market share through successful product launches, the licensing of a broad and differentiated product portfolio and strong customer relationships. Previously, Peter Goldschmidt was the Global Executive Member for Central and Eastern Europe where he led Sandoz to market leadership in generics and strongly grew the OTC business. He also held various senior leadership positions at Novartis Pharma in Asia and Europe during his career. Goldschmidt is a German national and holds a degree from the University of Muenster.
"Claudio Albrecht is making tremendous progress at STADA and will continue implementing the necessary reforms as CEO until later in the year. It has always been clear that he will then stay with STADA in a non-executive role, and we are delighted to have recruited an outstanding successor in Peter Goldschmidt," said Günter von Au, chairman of the STADA supervisory board. "The company is already in a good position to carry on with its successful renewal. At the same time, we are preserving the sense of continuity that is so vital to the development of STADA."
"Peter Goldschmidt is truly an excellent choice. I have known him for many years and hold him in very high esteem. I'm pleased especially for our 11,000 employees who now have a clear, long-term perspective for the leadership of the company," said Claudio Albrecht. "We are laying the foundation for the company's continued growth: A great deal has been achieved since September of last year. I will continue working full speed ahead to keep STADA on track for renewal until the transition of my role, and I look forward to staying close to the company in a non-executive role in the long term."
Peter Goldschmidt is looking forward to the new challenge: "Naturally I have known STADA as a key player in the industry for many years, and I see enormous potential in the company. It has also been evident from the outside that the company has recently experienced a healthy shake-up and many new initiatives were launched. I'm looking forward to working with all of the employees at STADA. Together we will strive to fully utilise the growth opportunities in the market."
About STADA Arzneimittel AG
STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. STADA consistently focuses on a multi-pillar strategy of generics and branded products (OTC) with an increasingly international market orientation. Worldwide, STADA is represented in more than 30 countries with more than 50 subsidiaries. Branded products such as Grippostad and Ladival are among the highest selling in their product categories in Germany. In financial year 2016, STADA achieved adjusted Group sales of Euro 2,167.2 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of Euro 398 million and adjusted net income of Euro 177.3 million. As of December 31, 2016, STADA employed 10,900 people worldwide.
Additional information for journalists
STADA Arzneimittel AG / Media Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany / Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail: firstname.lastname@example.org